KnowTheStock
Log inCreate free account

JOHNSON & JOHNSON

JNJ
S&P 500Dow 30Pharmaceutical Preparations · NYSE
$271.22last close · market cap 664.11 Billion
Compare with…
52.2SCORE / 100
Our verdictHOLDModerate Growth and ImprovingQtr Ending 2026-09-27 · trend positive

Why Hold

Income statement is strong; cash flow is moderate; balance sheet is weak.

Next earnings: 2026-10-13, EPS Forecast: $2.53

What is strong
  • Net Margin is 16.2%
  • Total Debt to Total Assets Ratio is 0.23
What to watch
  • Revenue Growth is 7.8%
  • Operating Income Growth is 2.67%
  • Net Income Growth is -35.92%
  • Earnings Per Share (EPS) Growth is -36.2%
  • Current Asset to Current Liability Ratio is 1.02
  • Debt Ratio is 0.59
  • Current Debt to Net Income Ratio is 42.15
  • Cash from Operations Growth is 8.08%
  • Capital Expenditure is High
  • Net Increase in Cash is Negative

What changed

Score by quarter

Upgraded from Sell to Hold in the Mar 2026 quarter: 52.6 → 52.4 (-0.2). This quarter: -3.2.

405060Apr 2023Sep 2026

What the score is made of

Income statement62.4 -2.2
Balance sheet30.5 -0.1
Cash flow56.9 -12.8

Change vs previous quarter.

Key numbers · latest quarter

Revenue (TTM)99.33 Billion7.80 % growth
EPS6.61-36.20 % growth
Profit margin16.20 %Profit per $1 of sales
P-E ratio—Not available
Market cap664.11 BillionShares × price
Debt-equity ratio0.55Leverage
Dividend5.28Per share, annual
Next earnings2026-10-13EPS forecast $2.53
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.

About JOHNSON & JOHNSON

Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.

CEO
Alex Gorsky
Employees
152,700
Sector
Manufacturing
Exchange
NYSE
jnj.com

Similar stocks

Loading…